Developer docs
API playgroundTry for free, no card

Search company profiles

Acurable

Full company profile

uuid00023so

Namestring
Acurable
Legal namestring
Acurable Ltd
Websiteurl
acurable.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Acurable Ltd is a London-based medical device company founded in 2016 as a spin-out from Imperial College London, developing wearable devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac sounds via a non-invasive neck-worn sensor. Recordings are transferred wirelessly to a mobile device and processed in a secure cloud platform by proprietary signal processing algorithms that automatically extract physiological parameters (AHI, ODI, SpO2, cardiac signal, respiratory phases, airflow, snoring, pulse rate, body position) and generate clinically validated diagnostic reports within minutes, without manual specialist interpretation.

The company's product family comprises three AcuPebble devices: SA100 (CE-marked home sleep apnea testing device and the first to receive CE mark for automated diagnosis of Obstructive Sleep Apnoea, also FDA 510(k) cleared in 2021), Ox100 (FDA-cleared 8-channel multi-channel home sleep study device launched in the US in 2023), and RE100 (continuous monitoring device for clinical research and post-market surveillance). The technology platform is positioned for Sleep Apnea, COPD, Epilepsy, and Asthma applications.

Acurable sells hardware to healthcare professionals and health systems through quote-based B2B enterprise contracts, with distribution via direct enterprise sales (NHS hospitals, sleep clinics, US health systems) and channel partners (Nyxoah for Germany). Revenue streams include device sales (SA100/Ox100/RE100) and cloud-based automated diagnosis services. The company has raised approximately €13m+ cumulatively across seed funding, Innovate UK grants, and an October 2022 €11m Series A led by Kibo Ventures with KHP Ventures participation, and operates from London and Seville with expansion into the US market.

Short descriptiontext

Acurable develops wearable medical devices based on proprietary acoustic sensing technology that enable automated home diagnosis and continuous monitoring of respiratory and cardiac conditions, primarily serving sleep clinics, NHS hospitals, US health systems, and pharmaceutical research organizations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable medical devices, sleep apnea diagnostics, home sleep testing, acoustic biosignal monitoring, respiratory care technology
Industry4 codes
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYCRACAIAG
Sleep Tech Wearables
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Sleep Apnea Diagnostic Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AcuPebble SA100 / Ox100 device sales
TypeHardware Sales
Description

Sale of wearable medical devices (AcuPebble SA100, AcuPebble Ox100, AcuPebble RE100) to healthcare professionals and health systems. The sensor is multi-use and rechargeable, sold alongside adhesives and accessories. Quote-based pricing for healthcare system procurement.

acurable.com
2Cloud-based automated diagnosis service
TypeSubscription Recurring
Description

Automated signal processing and diagnostic report generation via secure cloud platform. Part of the device ecosystem, potentially as an included or subscription component bundled with device sales.

acurable.com
3Clinical research and post-market surveillance (RE100)
TypeHardware Sales
Description

AcuPebble RE100 is used in clinical trials and post-market surveillance, sold to pharmaceutical companies and research institutions for data collection and monitoring.

acurable.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Quote-based B2B pricing for healthcare systems
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Contact sales for pricing information. Device sold to healthcare professionals and sleep clinics for use with patients.

acurable.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1AcuPebble
Description

Family of wearable medical devices based on acoustic sensing technology for sleep apnoea diagnosis and respiratory/cardiac monitoring.

acurable.com
+3 more records
Core offering1 text field

Acurable designs, manufactures, and sells the AcuPebble family of wearable medical devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac biosignals via a neck-worn sensor. The signals are processed by automated cloud-based algorithms to produce clinically validated diagnostic reports for obstructive sleep apnoea (SA100, Ox100) and continuous monitoring for clinical research (RE100). The devices are sold to healthcare professionals, sleep clinics, NHS and other public health systems, and pharmaceutical and clinical research organizations across the UK, Europe, and the US.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 94% positive predictive value and 98% negative predictive value compared to gold standard cardiorespiratory polygraphy (Royal Free Hospital trial, 150 patients)
+7 more records
Product overview1 text field

Acurable develops wearable medical devices based on proprietary acoustic sensing technology. The AcuPebble product family includes three products: AcuPebble SA100 (the CE-marked home sleep apnea testing device for Europe and UK), AcuPebble Ox100 (FDA-cleared version with 8-channel monitoring for the US market), and AcuPebble RE100 (research-focused device for clinical trials and remote patient monitoring). All devices use a non-invasive neck-worn acoustic sensor to record internal body sounds, which are processed by proprietary signal processing algorithms to automatically extract diagnostic parameters and generate sleep study reports.

Product and service3 records
1AcuPebble SA100
CategorySleep apnea diagnostic device
Description

CE-marked wearable home sleep apnea testing device for fully remote automated diagnosis of Obstructive Sleep Apnoea. A non-invasive neck sensor records acoustic biosignals that are automatically analyzed to generate a clinically validated sleep report equivalent to ambulatory gold-standard polygraphy, with no patient training and no manual specialist interpretation. Sold to sleep clinics, NHS hospitals, and other healthcare professionals.

2AcuPebble Ox100
CategorySleep apnea diagnostic device
Description

FDA-cleared multi-channel home sleep apnea testing device combining the AcuPebble neck sensor with a finger oximeter to produce a complete 8-channel sleep study report covering SpO2, cardiac signal, activity, respiratory phases, airflow, snoring, pulse rate, and body position. Targeted at the US sleep diagnostics market.

3AcuPebble RE100
CategoryClinical research monitoring device
Description

Continuous monitoring device for breathing and cardiac biosignals used in clinical research and post-market surveillance. Enables remote capture of clinically validated physiological parameters and biomarkers without requiring patients to remain in clinical environments. Sold to pharmaceutical companies and contract research organizations.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Strategic distribution agreement with Nyxoah to provide the AcuPebble SA100 home sleep test to the German market. This was announced alongside the Series A funding round.

Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2018-01-01
Description

Invited to join the Microsoft ScaleUp program for fast-growing start-ups in Europe in 2018. Provides access to Microsoft technology, resources, and network.

Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

Technology originated from over 10 years of research at Imperial College London's Wearable Technologies Lab, led by Prof. Esther Rodriguez-Villegas. IP was transferred to Acurable in 2016. Dr. Anas Imtiaz is also a research fellow at the Wearable Technologies Lab at Imperial College London.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

150-patient powered clinical trial comparing AcuPebble SA100 to multi-channel polygraphy. Led by Dr Swapna Mandal. Trial proved diagnostic equivalence and 100% patient usability. Results published in BMJ Open.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

California-based Magnap used AcuPebble device in a sleep apnea clinical trial at the University of California San Francisco. Dr Michael Harrison (professor of surgery and pediatrics at UCSF) called AcuPebble 'game-changing' for enabling multiple night studies.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Empatica develops FDA-cleared medical-grade wearables (EpiMonitor for epilepsy, Embrace) using biosensors and cloud analytics. It is comparable as a peer medical-grade wearable company with cloud-based diagnostic algorithms and similar regulatory milestones.

TypeDirect peer
Description

Nox Medical manufactures the Nox T3 and related polysomnography and home sleep testing systems widely used by sleep clinics and research institutions. It is a direct competitor in the HSAT and PSG category and overlaps with AcuPebble's clinical research and diagnostic use cases.

TypeEmerging player
Description

BioIntellisense produces the BioButton and BioSticker continuous remote monitoring wearables for vital signs and respiratory monitoring in hospitals and clinical trials. It overlaps with Acurable's clinical deterioration detection and pharma/CRO research use cases.

TypeDirect peer
Description

CleveMed produces the SleepScout and Sapphire PSG home sleep testing devices for sleep clinicians. It targets the same hospital and sleep lab customers as AcuPebble with portable PSG-class HSAT hardware.

TypeDirect peer
Description

SOMNOmedics is a German manufacturer of polysomnography and home sleep testing systems (SOMNOwatch, SOMNOscreen) used in European sleep medicine. It directly overlaps with AcuPebble in European clinical sleep diagnostics.

TypeBroad incumbent
Description

Philips Respironics offers Alice NightOne and other home sleep testing devices alongside its market-leading CPAP portfolio. As a broad incumbent in sleep medicine, it competes with AcuPebble on diagnostic workflows within hospital systems.

7Spire Health
TypeEmerging player
Description

Spire Health makes adhesive respiratory and sleep monitoring wearables for remote patient monitoring, including COPD and sleep apnea use cases. It overlaps with Acurable's RE100 research and remote monitoring positioning and targets similar enterprise healthcare customers.

TypeDirect peer
Description

Compumedics manufactures Somté and Siesta polysomnography and home sleep testing systems used by sleep clinics and research labs globally. It directly overlaps with AcuPebble's clinical diagnostic offering for sleep specialists.

TypeDirect peer
Description

Itamar Medical's WatchPAT is a leading FDA-cleared home sleep apnea testing device and the most direct competitor to AcuPebble SA100 in clinical-grade automated OSA diagnosis. Now part of ZOLL/ResMed, it competes head-to-head with AcuPebble for sleep clinic and cardiology channel accounts.

TypeBroad incumbent
Description

ResMed is the global leader in sleep apnea and respiratory care with CPAP/APAP therapy devices, masks, and increasingly home sleep diagnostics (via its ZOLL/Itamar acquisition). It is the dominant incumbent whose installed base and reimbursement infrastructure Acurable must compete against.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acurable

Sleep Apnea Diagnostic Devicesacurable.com

Acurable develops wearable medical devices based on proprietary acoustic sensing technology that enable automated home diagnosis and continuous monitoring of respiratory and cardiac conditions, primarily serving sleep clinics, NHS hospitals, US health systems, and pharmaceutical research organizations.

What Acurable does

Acurable Ltd is a London-based medical device company founded in 2016 as a spin-out from Imperial College London, developing wearable devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac sounds via a non-invasive neck-worn sensor. Recordings are transferred wirelessly to a mobile device and processed in a secure cloud platform by proprietary signal processing algorithms that automatically extract physiological parameters (AHI, ODI, SpO2, cardiac signal, respiratory phases, airflow, snoring, pulse rate, body position) and generate clinically validated diagnostic reports within minutes, without manual specialist interpretation.

The company's product family comprises three AcuPebble devices: SA100 (CE-marked home sleep apnea testing device and the first to receive CE mark for automated diagnosis of Obstructive Sleep Apnoea, also FDA 510(k) cleared in 2021), Ox100 (FDA-cleared 8-channel multi-channel home sleep study device launched in the US in 2023), and RE100 (continuous monitoring device for clinical research and post-market surveillance). The technology platform is positioned for Sleep Apnea, COPD, Epilepsy, and Asthma applications.

Acurable sells hardware to healthcare professionals and health systems through quote-based B2B enterprise contracts, with distribution via direct enterprise sales (NHS hospitals, sleep clinics, US health systems) and channel partners (Nyxoah for Germany). Revenue streams include device sales (SA100/Ox100/RE100) and cloud-based automated diagnosis services. The company has raised approximately €13m+ cumulatively across seed funding, Innovate UK grants, and an October 2022 €11m Series A led by Kibo Ventures with KHP Ventures participation, and operates from London and Seville with expansion into the US market.

Acurable firmographics

Firmographics
Name
Acurable
Legal name
Acurable Ltd
Website
https://acurable.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Acurable develops wearable medical devices based on proprietary acoustic sensing technology that enable automated home diagnosis and continuous monitoring of respiratory and cardiac conditions, primarily serving sleep clinics, NHS hospitals, US health systems, and pharmaceutical research organizations.
Ownership category
akta.pro rank

Acurable industry classification

Industry
Product category
Sleep Apnea Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYCRACAIAG
Sleep Tech Wearables

Keywords

  • Wearable medical devices
  • Sleep apnea diagnostics
  • Home sleep testing
  • Acoustic biosignal monitoring
  • Respiratory care technology

Where Acurable is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Acurable business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. AcuPebble SA100 / Ox100 device sales: Sale of wearable medical devices (AcuPebble SA100, AcuPebble Ox100, AcuPebble RE100) to healthcare professionals and health systems. The sensor is multi-use and rechargeable, sold alongside adhesives and accessories. Quote-based pricing for healthcare system procurement.
  2. Cloud-based automated diagnosis service: Automated signal processing and diagnostic report generation via secure cloud platform. Part of the device ecosystem, potentially as an included or subscription component bundled with device sales.
  3. Clinical research and post-market surveillance (RE100): AcuPebble RE100 is used in clinical trials and post-market surveillance, sold to pharmaceutical companies and research institutions for data collection and monitoring.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based B2B pricing for healthcare systems

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Acurable product offering

Product offering

Core offering

Acurable designs, manufactures, and sells the AcuPebble family of wearable medical devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac biosignals via a neck-worn sensor. The signals are processed by automated cloud-based algorithms to produce clinically validated diagnostic reports for obstructive sleep apnoea (SA100, Ox100) and continuous monitoring for clinical research (RE100). The devices are sold to healthcare professionals, sleep clinics, NHS and other public health systems, and pharmaceutical and clinical research organizations across the UK, Europe, and the US.

Product overview

Acurable develops wearable medical devices based on proprietary acoustic sensing technology. The AcuPebble product family includes three products: AcuPebble SA100 (the CE-marked home sleep apnea testing device for Europe and UK), AcuPebble Ox100 (FDA-cleared version with 8-channel monitoring for the US market), and AcuPebble RE100 (research-focused device for clinical trials and remote patient monitoring). All devices use a non-invasive neck-worn acoustic sensor to record internal body sounds, which are processed by proprietary signal processing algorithms to automatically extract diagnostic parameters and generate sleep study reports.

Differentiator

Problem solved

Functional benefit

Brands

  • AcuPebble: Family of wearable medical devices based on acoustic sensing technology for sleep apnoea diagnosis and respiratory/cardiac monitoring.
  • AcuPebble SA100
  • AcuPebble Ox100
  • AcuPebble RE100

Products and services

  • AcuPebble SA100 CE-marked wearable home sleep apnea testing device for fully remote automated diagnosis of Obstructive Sleep Apnoea. A non-invasive neck sensor records acoustic biosignals that are automatically analyzed to generate a clinically validated sleep report equivalent to ambulatory gold-standard polygraphy, with no patient training and no manual specialist interpretation. Sold to sleep clinics, NHS hospitals, and other healthcare professionals.
  • AcuPebble Ox100 FDA-cleared multi-channel home sleep apnea testing device combining the AcuPebble neck sensor with a finger oximeter to produce a complete 8-channel sleep study report covering SpO2, cardiac signal, activity, respiratory phases, airflow, snoring, pulse rate, and body position. Targeted at the US sleep diagnostics market.
  • AcuPebble RE100 Continuous monitoring device for breathing and cardiac biosignals used in clinical research and post-market surveillance. Enables remote capture of clinically validated physiological parameters and biomarkers without requiring patients to remain in clinical environments. Sold to pharmaceutical companies and contract research organizations.

Quantifiable outcome

  • 94% positive predictive value and 98% negative predictive value compared to gold standard cardiorespiratory polygraphy (Royal Free Hospital trial, 150 patients)
  • +7 more outcomes

Companies that use Acurable

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Acurable technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Acurable partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered key, supporting and foundational.

  • NyxoahkeyChannel Partner/ Reseller/ Distributor · 1 January 2022Strategic distribution agreement with Nyxoah to provide the AcuPebble SA100 home sleep test to the German market. This was announced alongside the Series A funding round.
  • Microsoft ScaleUpsupportingGTM or Marketing Partner · 1 January 2018Invited to join the Microsoft ScaleUp program for fast-growing start-ups in Europe in 2018. Provides access to Microsoft technology, resources, and network.
  • Imperial College LondonfoundationalStrategic or Co-development PartnerTechnology originated from over 10 years of research at Imperial College London's Wearable Technologies Lab, led by Prof. Esther Rodriguez-Villegas. IP was transferred to Acurable in 2016. Dr. Anas Imtiaz is also a research fellow at the Wearable Technologies Lab at Imperial College London.
  • Royal Free Hospital NHS Foundation TrustkeyStrategic or Co-development Partner150-patient powered clinical trial comparing AcuPebble SA100 to multi-channel polygraphy. Led by Dr Swapna Mandal. Trial proved diagnostic equivalence and 100% patient usability. Results published in BMJ Open.
  • UCSF / MagnapkeyStrategic or Co-development PartnerCalifornia-based Magnap used AcuPebble device in a sleep apnea clinical trial at the University of California San Francisco. Dr Michael Harrison (professor of surgery and pediatrics at UCSF) called AcuPebble 'game-changing' for enabling multiple night studies.

Scale indicators11 records

Recent moves10 records

Expansion highlights8 records

Acurable competitors and assessment

Company assessment

Emerging players

  • Empatica: Empatica develops FDA-cleared medical-grade wearables (EpiMonitor for epilepsy, Embrace) using biosensors and cloud analytics. It is comparable as a peer medical-grade wearable company with cloud-based diagnostic algorithms and similar regulatory milestones.
  • BioIntellisense: BioIntellisense produces the BioButton and BioSticker continuous remote monitoring wearables for vital signs and respiratory monitoring in hospitals and clinical trials. It overlaps with Acurable's clinical deterioration detection and pharma/CRO research use cases.
  • Spire Health: Spire Health makes adhesive respiratory and sleep monitoring wearables for remote patient monitoring, including COPD and sleep apnea use cases. It overlaps with Acurable's RE100 research and remote monitoring positioning and targets similar enterprise healthcare customers.

Direct peers

  • Nox Medical: Nox Medical manufactures the Nox T3 and related polysomnography and home sleep testing systems widely used by sleep clinics and research institutions. It is a direct competitor in the HSAT and PSG category and overlaps with AcuPebble's clinical research and diagnostic use cases.
  • CleveMed: CleveMed produces the SleepScout and Sapphire PSG home sleep testing devices for sleep clinicians. It targets the same hospital and sleep lab customers as AcuPebble with portable PSG-class HSAT hardware.
  • SOMNOmedics: SOMNOmedics is a German manufacturer of polysomnography and home sleep testing systems (SOMNOwatch, SOMNOscreen) used in European sleep medicine. It directly overlaps with AcuPebble in European clinical sleep diagnostics.
  • Compumedics: Compumedics manufactures Somté and Siesta polysomnography and home sleep testing systems used by sleep clinics and research labs globally. It directly overlaps with AcuPebble's clinical diagnostic offering for sleep specialists.
  • Itamar Medical (ZOLL Itamar, WatchPAT): Itamar Medical's WatchPAT is a leading FDA-cleared home sleep apnea testing device and the most direct competitor to AcuPebble SA100 in clinical-grade automated OSA diagnosis. Now part of ZOLL/ResMed, it competes head-to-head with AcuPebble for sleep clinic and cardiology channel accounts.

Broad incumbents

  • Philips Respironics: Philips Respironics offers Alice NightOne and other home sleep testing devices alongside its market-leading CPAP portfolio. As a broad incumbent in sleep medicine, it competes with AcuPebble on diagnostic workflows within hospital systems.
  • ResMed: ResMed is the global leader in sleep apnea and respiratory care with CPAP/APAP therapy devices, masks, and increasingly home sleep diagnostics (via its ZOLL/Itamar acquisition). It is the dominant incumbent whose installed base and reimbursement infrastructure Acurable must compete against.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Acurable social profiles

Digital presence

Acurable compliance and trust

Trust signal

Compliance6 records

Acurable financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acurable leadership team

Management profile

Number of profiles

Profiles3 records

Acurable funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acurable M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acurable

What does Acurable do?

Acurable designs, manufactures, and sells the AcuPebble family of wearable medical devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac biosignals via a neck-worn sensor. The signals are processed by automated cloud-based algorithms to produce clinically validated diagnostic reports for obstructive sleep apnoea (SA100, Ox100) and continuous monitoring for clinical research (RE100). The devices are sold to healthcare professionals, sleep clinics, NHS and other public health systems, and pharmaceutical and clinical research organizations across the UK, Europe, and the US.

Is Acurable a public or private company?

Acurable is a private company. It is classified as venture growth investor backed and is currently operating.

When was Acurable founded?

Acurable was founded in 2016. It employs 11 to 50 people.

Where is Acurable based?

Acurable is headquartered in London, United Kingdom, in the Europe region.

How does Acurable make money?

Three revenue lines are on record. AcuPebble SA100 / Ox100 device sales are the primary driver. The others are cloud-based automated diagnosis service and clinical research and post-market surveillance (RE100).

Who are Acurable's main competitors?

Emerging players on record are Empatica, BioIntellisense and Spire Health. Direct peers are Nox Medical, CleveMed, SOMNOmedics, Compumedics and Itamar Medical (ZOLL Itamar, WatchPAT). Broad incumbents are Philips Respironics and ResMed.

Does Acurable have an API?

No public API is recorded for Acurable.

What industry is Acurable in?

Acurable's product category is Sleep Apnea Diagnostic Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Med-Tech InsightsUK MedTech Company Named in TIME Magazine 2026 Top Companies ListAcurable, a UK medical devices company, was named in TIME's 2026 World's Top HealthTech Companies list. Its AcuPebble wearable device diagnoses sleep apnoea at home, and the company says it is now used in the NHS for remote diagnosis.Respiratory TherapyNew Home Sleep Apnea Testing Device to Launch in USUnited Kingdom-based medical device company Acurable will launch its AcuPebble device for obstructive sleep apnea diagnosis in the United States this summer following recent FDA clearance. The company recently secured a $12 million Series A funding round to support this expansion into the US market. This move follows the device's established use in the UK National Health Service and aims to provide a patient-friendly, remote testing alternative.TechCrunchMeet the tiny, wireless sleep apnea diagnostic wearable headed for the USAcurable, a U.K. medtech startup, received FDA clearance for its AcuPebble wearable to remotely diagnose obstructive sleep apnea. The device, already used in U.K. hospitals, will launch in the U.S. this summer. The company plans to expand its team by 300% and eventually sell consumer products.LinkedIn#medtech #innovation #ukri #healthcare #researchAcurable has been awarded an Innovate UK grant to adapt its AcuPebble technology for the early detection of clinical deterioration in patients. The sensor enables remote monitoring by measuring subtle cardiac and respiratory signals, aiming to reduce hospital admissions and deaths from conditions like sepsis and cardiac arrest.Empresas de Capital Riesgo en EspaAcurable raises €11m in Series A funding round led by Kibo Ventures, along with Mundi Ventures, Kindred Capital, and Comprador Holdings among othersAcurable announced an €11 million Series A funding round led by Kibo Ventures, with participation from Mundi Ventures, Kindred Capital, and Comprador Holdings. The company intends to use the capital to accelerate the international expansion of its AcuPebble SA100 home sleep testing device into European markets and North America. This move follows a recent strategic distribution agreement with Nyxoah for the German market.BusinessCloudWearable tech firm goes global after £9.5m fundraiseAcurable, a London-based wearable medical device firm, raised £9.5m in Series A funding led by Kibo Ventures. The funds will accelerate international expansion of its AcuPebble SA100, which has CE and FDA clearance, toward diagnosing one million patients.BusinessCloudWearable tech firm goes global after £9.5m fundraiseAcurable, a London-based wearable medical device firm, raised £9.5m in Series A funding led by Kibo Ventures. The funds will accelerate international expansion of its AcuPebble SA100, which has CE and FDA clearance for home sleep apnoea diagnosis. The company aims to diagnose one million patients.FinSMEsAcurable Raises €11M in Series A Funding RoundAcurable raised €11 million in a Series A funding round led by Kibo Ventures, with participation from Mundi Ventures, Kindred Capital, and Comprador Holdings. The company plans to use the capital to expand its distribution network for the AcuPebble SA100 home sleep testing device across Europe and North America, while investing in new product development based on this technology.Business Wire BlogWearable Medical Devices Company Acurable Raises €11m in Series A Funding RoundAcurable announced an €11m investment from its Series A funding round to accelerate the international rollout of its home sleep testing device, AcuPebble SA100. This funding will support the expansion into major European markets and North America, aiming to address the significant unmet needs in diagnosing obstructive sleep apnoea. The device has already received significant regulatory approvals, including CE marking in Europe and FDA clearance in the US, allowing for automated home testing of patients.BioSpaceWearable Medical Devices Company Acurable Raises €11m in Series A Funding RoundWearable medical devices company Acurable has raised €11m in a Series A funding round. The capital will be used to expand distribution for its home sleep testing device, AcuPebble SA100, into major European and North American markets. Additionally, the funds will support the development of new products based on the same technology for respiratory and cardiovascular conditions.